Jump to content

FIRE, EXP: MJ, & other Marijuana stocks

Recommended Posts

Experion / EXP: MJ & other Marijuana stocks


Viridium Pacific Ltd - VIR.v /was MRB.v : Marijuana Labs

(here's the future for an almost-dead mining exploration company, whose shares I held)

Morro Bay Resources Ltd > Viridium Pacific Ltd ... with reverse split coming...

"a reverse take-over of Morro Bay by Experion"

Morro Bay Resources Ltd WAS engaged in gold-silver exploration with mineral interests in the Penoles Project in Mexico.

The Company has operations in Penoles, Mexico."

MJ / Alternative Health index, WEED, FIRE, EXP ... update: at 12/23/19: $17.14, C$26.27, C$0.66, C$0.105



VIR / Viridium Pacific / MRB : Morro Bay. ... all-data : 5-yr : 2-yr : 12mo ::

8/4/2017 : lo:$0.05 - hi:C$0.25: $0,902 / x 3,606 = $0,541 @ C$0.15



Morro Bay / VIR – Split 10-1 in May, then 3.603 for one last week (10/12)

shs os: 9,180,096 : 100.% x C$ 0.15 = C$ 1.37 million

other : 0,482,998 : 5.26% : John Zang

Reverse Takeover Transaction coming:

0. starting shares outstanding : 09,180,096

1. issue shares for debts------ : 02,781,094


Shs OS prior consolidation : 11, 961,290

Shs OS after consolidation : 2,903,618 : at a rate of: 1 / 4.119443 :: $0.15 x 4.119= C$ 0.61785

2. issue to Experion ------------ : 41,767,086 - post consolidation shs, to own 93.5%

Total shs OS, post-consol. : 44,670,704 : x C$0.618 = C$ 27.6 million.

Calgary, Alberta (FSCwire) - Morro Bay Resources Ltd. (“Morro Bay” or the “Company”) (TSXV: MRB, OTCPink: MRRBF) is pleased to provide an update and additional information in regard to the proposed reverse takeover transaction announced by Morro Bay on May 23, 2017 (the “Transaction”).

Update on the Transaction

As announced on May 23, 2017, Morro Bay has made an offer to acquire all of the outstanding shares of a private company located in British Columbia (the “Offer”). The private company’s name is Experion Biotechnologies Inc. (“Experion”). As previously announced, the Offer was made on May 15, 2017, and is open for acceptance by the Experion shareholders within thirty (30) days after delivery (therefore being approximately June 16, 2017) unless otherwise extended by Morro Bay. Pursuant to the Offer, Morro Bay has offered to issue to the Experion shareholders 205,500,000 Morro Bay common shares in exchange for all of the issued and outstanding shares of Experion. The deemed value per share is $0.1217 per Morro Bay Share (the total deemed value is approximately $25 million). The delivery of 205,500,000 Morro Bay common shares will result in the Experion shareholders owning approximately 93% of Morro Bay’s common shares...

Additional information concerning the Offer is contained in the News Release dated May 23, 2017.

Read more at http://www.stockhouse.com/news/press-releases/2017/06/07/morro-bay-resources-ltd-provides-further-details-on-the-proposed-reverse#Ga0lQPEiE7D69wRe.99

/ 2 /

As was announced on May 23, 2017, Experion is a Canadian biotech company focused on two lines of business:

1. Completion and operation of a controlled substances laboratory through an affiliate company (the “Lab Business”).

2. Obtaining a license to produce and to distribute medical cannabis products from Health Canada (the “Licensed Producer Business”) pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”).

Experion is incorporated pursuant to the British Columbia Business Corporations Act and all of its assets are located in British Columbia. Experion currently has 13,333,333 Class “A” common shares outstanding. Experion has no other securities issued or outstanding.

The Lab Business: The Lab Business is expected to be in operation by July 2017. The Lab Business is operated by an affiliate of Experion—Northern Vine Canada Inc. The Lab Business has obtained a Controlled Substance License from Health Canada. Upon commencement of its operations, the Lab Business will become a laboratory service provider for the Canadian medical cannabis industry. As has been recently reported, unauthorized pesticides in some cannabis products have been a cause for increased focus on the safety of the Canadian medical marijuana supply by all levels of governments and end customers. The Lab Business is expected to help fill the current void in testing, and be available to licensed producers to test marijuana products. Testing is expected to include determination of chemical components and potency of products, physical testing, microbial analysis, and chemical contaminants testing.

The Licensed Producer Business: Experion is proceeding to obtain all necessary licenses and authorizations permitting it to become a licensed producer of medical marijuana pursuant to the ACMPR (the “ACMPR License”). Experion has applied to Health Canada for an ACMPR License to cultivate medical marijuana and has successfully completed the “review” stage of the Health Canada licensing process. This means that Experion received a “Confirmation of Readiness” letter from Health Canada (also known as a “ready to build” letter) in June 2016. In early June 2017, Experion expects to request its Pre-license Inspection by Health Canada.

Experion anticipates completion of construction of its state-of-the-art indoor production, secure storage and processing facility located in Mission, British Columbia (the “Mission Site”) by June 30, 2017. Upon substantial completion of construction at the Mission Site, it will be made available for the Health Canada inspection. Upon completion of a satisfactory Pre-License Inspection by Health Canada, Experion expects to be authorized to commence the cultivation of medical marijuana.

Upon receipt of its ACMPR License, Experion plans to commence the cultivation of medical-grade marijuana with a focus of growing whole plant “starter material” for wholesale distribution to licensed growers and the production and processing of dried cannabis flower for wholesale distribution. The Mission Site facility is 8,300 square feet of which approximately 2,000 square feet will be used to grow medical-grade marijuana. Experion also plans to expand its production facilities by constructing 40,000 square feet of greenhouse canopy (the “Greenhouse”), subject to Health Canada approval, for whole plant cultivation.

The above description of the Licensed Producer Business is conditional on Experion receiving its license under the ACMPR. Experion is essentially a late-stage license applicant.

As of May 31, 2017, Experion had $1,260,685 on deposit with its bank. Experion anticipates that the major expenditures during June and July 2017 will be the costs related to the Transaction and the balance of the costs related to the completion of the Mission Site facility to be used in the Licensed Producer Business. Construction of the Mission Site facility is ahead of schedule and currently below budget. Completion of the Mission Site facility is anticipated to occur by June 30, 2017, with total additional costs to be incurred to complete the facility estimated by Experion management to be approximately $290,141.

Link to comment
Share on other sites

Bad News for Canadian Marijuana Stocks:

Say Hello to Your New Competition Health Canada may be about to open the floodgates for licensed cannabis growers.

Sean Williams
Jul 17, 2017 at 9:38AM

When it comes to North America's fastest-growing industries, chances are you'd struggle to find any with a higher, more consistent growth rate than legal marijuana. And investors know it, which is a big reason some of the largest marijuana stocks have risen by 100%, 200%, or even more, over the trailing one-year period.

According to cannabis research firm ArcView, North American sales of legal pot, both recreational and medical, soared 34% in 2016 to $6.9 billion, and they're expected to grow by an average of 26% through 2021 to nearly $22 billion. This growth is expected to come from legalization of the substance -- Mexico recently legalized medical cannabis throughout the country, and eight states have legalized recreational weed in the U.S. since November 2012 -- and organic growth from states and countries where the drug is already legal. In Canada, for instance, the number of eligible medical patients has been growing at a pace of almost 10% per month, according to Health Canada.

Pot stocks face numerous challenges

But the weed landscape isn't perfect. Marijuana stocks also face a plethora of challenges each and every day.

As an example, U.S.-based cannabis companies have little or no access to basic banking services. Financial institutions in the U.S. report to the Federal Deposit Insurance Corporation, which is a federally created entity. Since marijuana is a Schedule I, and ergo illicit, substance at the federal level, banks deny financial services (even checking accounts) to pot businesses for fear of fines or criminal penalties under a strict interpretation of federal law. That means these businesses have to rely solely on cash, which is a big security concern.

Weed-based companies also get no love come tax time. Because they sell a Schedule I substance, they're disallowed from taking normal corporate income-tax deductions. Profitable marijuana companies are left to pay tax on their gross profits instead of their net profits, leaving less money to reinvest in the business.

Throughout North America, marijuana stocks are also subject to political challenges. In the U.S., industry opponents such as Attorney General Jeff Sessions stand at the ready to trample states' rights and prosecute medical-marijuana businesses. Meanwhile, conservatives in Canada's parliament are doing what they can to halt the progress of a recreational legalization bill that Prime Minister Justin Trudeau introduced earlier this year. Conservatives in Canada argue that a home-grow option in the bill would give minors easy access to cannabis, and that a lack of DUI guidelines for marijuana use make legalizing the drug dangerous.

Bad news for Canadian marijuana stocks

Well, I have news for marijuana stock investors: There's a new threat on the horizon, at least for our neighbors to the north.

In May, Health Canada, the regulatory agency that seeks to protect the medical welfare of Canada's citizens, announced that it was making a number of changes to the country's medical marijuana program. Some of these changes included eliminating the red tape associated with gaining licensing approval for production. However, the big change it announced was that it would increase the number of licensed cannabis producers. As of May 24, there were only 44 licensed producers throughout the country, but 187 applications were at the review stage. It seems unlikely that the number of licensed producers is going to quintuple overnight since not every application will be accepted, but there's a real possibility of significant near-term licensed producer growth.

Right now, Canada's biggest medical growers include Canopy Growth Corp.(NASDAQOTH:TWMJF), Aphria (NASDAQOTH:APHQF), Aurora Cannabis(NASDAQOTH:ACBFF), and the recently public MedReleaf (NASDAQOTH:MEDFF)(TSX:LEAF). This news suggests that all four will soon face a significant uptick in competition, making their expansionary efforts all the more important, with Canada tinkering with the idea of legalizing recreational weed.

Canopy Growth Corp. recently completed the acquisition of Mettrum Health, boosting its medical patient reach throughout Canada, and it also purchased 472,000 square feet of land housing and surrounding its headquarters. This should allow it to further boost its production capacity.

Meanwhile, the other three industry juggernauts have stuck to more organic methods of capacity expansion. Aphria's $100 million capital project, known as Phase IV, will boost capacity to 1 million square feet and 75,000 kilograms of cannabis annually when completed. Aurora Cannabis' Aurora Sky project is a mammoth 800,000-square-foot facility that could very well be the most automated and technologically advanced grow facility when finished. And finally, MedReleaf is using its initial public offering proceeds to expand capacity at its Bradford, Ontario facility.

A grim reality

Just how badly could this increase in competition sting the likes of Canopy Growth, Aurora Cannabis, Aphria, MedReleaf, and its peers? According to a recently released analyst note from Neil Maruoka of Canaccord Genuity, Health Canada's willingness to grant more licenses means it's unlikely that any one company will control more than 20% of cannabis supply.

Said Maruoka: "Our projections of respective market sizes remain largely unchanged, and while we remain confident this growth can be achieved, we also believe the significant increase in granted licenses is likely to create stronger competition among LPs [licensed producers]. We continue to expect that established producers with solid balance sheets, such as Canopy, Aphria, and Aurora, are likely to emerge as dominant players; however, we no longer feel it is reasonable to assume that any one LP can capture over 20% share of a likely increasingly crowded market."

Maruoka and his firm wound up lowering their respective market share estimates for leader Canopy Growth to 15% of the recreational market (assuming approval) and 12% of the medical market, down from an initial share forecast of 21% and 17.5%, respectively. Canaccord also expects Aurora Cannabis to be second with 10% of recreational and medical market share, and Aphria third with a 9% recreational and 7.5% medical share.

Not surprisingly, Maruoka and his firm also lowered their price targets for a half-dozen marijuana stocks and reduced their rating on five of six companies. As a sign of how far Aphria has fallen from its 52-week high, it was actually upgraded even though its share-price target was modestly lowered.

All bets are off

Despite its consistently strong growth rate, there simply aren't any guarantees at this point that success awaits marijuana stocks. There have been some encouraging early signs of profitability, albeit minimal, from companies such as Canopy Growth, Aphria, and MedReleaf, but at the same time, there aren't any assurances that Trudeau can get his recreational-cannabis legislation signed into law. After all, he's been pushing for legalization for years without any progress, so what's to say with any certainty that it happens now?

With competition increasing, the future uncertain, and most marijuana stocks either unprofitable or valued at nosebleed P/E ratios, your best bet for the time being is to steer clear of the industry.

Marijuana stocks are overhyped: 10 better buys for you now
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and marijuana stocks were noticeably absent! That's right -- they think these 10 stocks are better buys.

Learn more

*Stock Advisor returns as of July 6, 2017

Read more at http://www.stockhouse.com/companies/bullboard#1f85FOCu2cJa0grg.99
Link to comment
Share on other sites

Canada's main Cannabis-related, medical growers


" We continue to expect that established producers with solid balance sheets, such as Canopy, Aphria, and Aurora,

are likely to emerge as dominant players;" - Canaccord


Canada's biggest medical growers include

Canopy Growth Corp.(NASDAQOTH:TWMJF),


Aurora Cannabis (NASDAQOTH:ACBFF), and the recently public




Canopy Growth Corp. WEED.T (NASDAQOTH:TWMJF) ... all-data : 2yrs : 12mos :



Aphria Inc. APH (NASDAQOTH:APHQF), ... all-data : 2yrs : 12mos :



Aurora Cannabis ACB (NASDAQOTH:ACBFF), ... all-data : 2yrs : 12mos :



and the recently public :

MedReleaf (NASDAQOTH:MEDFF)(TSX:LEAF). ... all-data : 2yrs : 12mos :


Link to comment
Share on other sites

  • 2 months later...

Dear Reader,

Justin Spittler, editor of the Casey Daily Dispatch, here.

For the last few months, I’ve been pounding the pavement on the massive profit potential in pot stocks.

I’ve shown you how Doug made 1,900% gains on a penny pot stock.

How the best of these pot stocks averaged 29,000% gains.

I even told you about three pot stocks to buy right now.




Morro Bay / VIR – Split 10-1 in May, then 3.603 for one last week

Link to comment
Share on other sites

  • 2 weeks later...

Marijuana real estate is big business…

And the world's first publicly traded REIT for pot gives you the chance to cash in big… without buying, selling, or investing in real estate yourself.

Here's how it works…


Landlords renting to growers make up to 260% more revenue.

Farmers bring in 10 times more money.

But the high rates growers pay kills cash flow.

This marijuana REIT is buying up the most valuable land in the world. And leasing it back to growers.

Growers get the cash they need to expand.

And the REIT cashes in big by charging premium rates for the land.

If you buy stock in this company, you instantly own some of the most profitable real estate on earth.

And because this is a REIT, it must pay out at least 90% of its taxable income as dividends.

It went public in December 2016.And it's already paying out dividends on profits.

And this is just one of 3 pot stocks we see exploding soon.

While nothing in the market is guaranteed, we're expecting a new law to revolutionize the marijuana industry.

All indications are that the law will move forward by October 31.

And if it does, these 3 marijuana stocks could go through the roof. So now is the perfect time to take advantage of marijuana mania. Get the whole story here.

To your personal pot profits,

Justin Spittler
Editor, Casey Daily Dispatch
Link to comment
Share on other sites


Investment Objective

Achieve long-term capital appreciation by investing in companies operating in the North American cannabis industry.

The Fund’s investment focus will be on low risk ancillary services, brands and consumer applications that underlie and support the legalized cannabis industry. The Fund will not have direct invest- ment exposure in companies that are growers or distributors of the cannabis plant itself.

The Investment Advisor

Nesta Holding Co. Ltd is a Canadian based private equity rm investing in the North American cannabis industry. The company was founded in 2015 by Chuck Ri ci the former founder and CEO of ...

Canopy Growth Corp. (TSX:CGC / WEED) ... update


Since its inception, Nesta has grown its AUM by nearly 300% focus- ing on scalable, high margin ancillary opportunities servicing the cannabis industry: digital services, consumer application technolo- gy, brand IP as well as alternative nancing vehicles – opportunities that leverage the tremendous growth of the North American canna- bis industry without the regulatory risk.

The Market Opportunity

ArcView Market Research projects the legalized North American cannabis industry will top US$22.6 billion by 2021, growing at a 27% annual CAGR. Still, large institutional investors are reluctant to invest due to acute regulatory uncertainty, despite the growth trajectory.

The high customer demand for legal cannabis combined with the arti cially restricted availability to capital to fund consumer brands and applications creates a very large market opportunity for Nesta.

Target Investments

One Web Services: the largest price comparison web-site and mo- bile app for the U.S. cannabis industry. (www.wikileaf.com)

Feather Co: manufacturer of pre- lled disposable vaporizers target- ing recreationally legal states in the U.S. (www.feather.co)

Kush Bottles: Leading wholesaler of marijuana & cannabis compli- ant packaging. (www.kushbottles.com)

Exit Strategy

The Fund’s investment returns will be largely achieved through capital growth. Thus, a key to any new investment appraisal will be the potential for successful realization of value within 3-5 years from the date of initial investment. With anticipated enterprise values on exit of between $30m and $100m, the investee companies will be ex- pected to provide realistic secondary/buy-out opportunities as well as the prospect of an IPO, depending on the market environment at the time.



Chuck Ri ci: Chairman & CEO of Nesta Holding Co. Ltd., previously founder and CEO of Canopy Growth Corp., North America’s largest cannabis company

Manoj Hippola: Managing Director and CIO of Nesta Holding Co. Ltd; previously CFO with a publicly listed U.S. company

Nigel Eyles Managing Director, Nesta Europe S.A. previously in senior institutional sales roles with UBS and Lehman Brothers

Link to comment
Share on other sites

  • 7 months later...
  • 2 weeks later...

Viridium - Stock price history still matters... apparently

VIR... update : 2yrs :


Link to comment
Share on other sites

  • 2 months later...
  • 11 months later...

Canopy Growth, world’s largest pot company, lost $1 billion in three months MarketWatch

Stock falls 10% in late trading after elimination of C$1.18 billion in warrants related to Constellation Brands investment leads to earnings miss

MW-HL702_Canopy_20190619111841_ZH.jpg?uuBloomberg News/Landov
Analysts surveyed by FactSet had estimated fiscal first-quarter adjusted losses of C$0.38 a share on revenue of C$111.9 million

Canopy Growth Corp. reported a C$1.28 billion quarterly loss late Wednesday and missed analyst revenue estimates for revenue, sending shares down 10% in after-hours trading.

The world’s largest cannabis company by market value, Canopy Growth CGC, -6.64% WEED, -5.76%  reported fiscal first-quarter net losses of C$1.28 billion, or C$3.70 a share, compared with losses of C$91 million, or 40 cents a share, in the year-ago period. The more than $1 billion loss was due to the company extinguishing warrants related to the Constellation Brands Inc. STZ, -1.61%  investment.

Canopy Growth fired co-Chief Executive Bruce Linton not long after its previous earnings report, amid reports of unhappiness at Constellation with continuing large losses. CEO Mark Zekulin has remained at the helm of the company, but has said he expects to exit once a new leader is found.

Net revenue rose to C$90.5 million from C$25.9 million in the year-ago period, excluding excise taxes. Of that revenue, Canopy said that C$50.4 million was Canadian recreational business-to-business, C$10.6 was direct to consumer and C$13.1 million was medical cannabis sales. Canopy also brought in $10.5 million in international cannabis revenue.

Analysts surveyed by FactSet had estimated fiscal first quarter adjusted losses of C$0.38 a share on revenue of C$111.9 million. Canopy did not provide any per-share adjusted-earnings information.

Link to comment
Share on other sites

I am happy I dumped this shortly after the foray into Marijuana labs

VIR > EXP / EXPERION Holdings ... all-data : vs-WEED : 5-yr : 2-yr : 12mo ::


: EXP-vs-WEED :


“Experion Holdings Ltd.” (TSX-V: EXP).

June 10, 2019 (Source) – Viridium Pacific Group Ltd. (the ”Company”) (TSX-V: VIR ) is pleased to announce that the Company has changed its name from “Viridium Pacific Group Ltd.” to “Experion Holdings Ltd.” (TSX-V: EXP).The Company’s shareholders approved the name change at a special meeting of shareholders held on May 31, 2019. Effective on market opening on June 10, 2019, the common shares of the Company will commence trading on the TSX Venture Exchange under the Company’s new name, Experion Holdings Ltd., and under the trading symbol ”EXP”. With the new change in name, there is no consolidation of capital and the CUSIP Number will be 30219B109.

Mr. Jay Garnett, Chief Executive Officer, commented, “We are excited to have both our Licence and corporate entity under Experion. Having a focused brand strategy, under one corporate brand, will bring alignment to the market and our shareholders. In addition, it will allow us to better communicate our value proposition as we work to unlock value and communicate our accomplishments to the market and stakeholders.”

No action is required to be taken by current shareholders in connection with the change in name and no change has been made to Experion Holdings Ltd. share capital.

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Link to comment
Share on other sites

Experion Holdings Ltd  Update

Recent Bulletins News ReleasesIn The NewsOther
Date ET Symbol Price Type Headline
2019-08-06 09:51 C:EXP 0.215 News Release Experion has claim for 10.27 M shares dismissed
2019-07-25 11:08 C:EXP 0.24 News Release Experion's chairman McWatters dies
2019-07-24 13:19 C:EXP 0.24 News Release Experion files Q2 financials, talks recent work
2019-07-24 12:23 C:EXP 0.24 SEDAR Interim Financial Statements SEDAR Interim Financial Statements
2019-07-24 12:23 C:EXP 0.24 SEDAR MD & A SEDAR MD & A
VANCOUVER, British Columbia, July 24, 2019 (FSCwire) Experion Holdings Ltd. (“Experion” ...


Experion has now filed its Q2 2019 consolidated interim financial statements, and management discussion and analysis for the six months ended May 31, 2019 on SEDAR.

Business Update – Domestic and International Market Development

Domestic Market:

In January 2019, the Company begun to sell clones to newly licensed Standard Cultivators looking for quality genetics to launch their cultivation process. The sales expand Experion’s product line with clones exhibiting the desired specifications and attributes for both the medical and Adult-use market.  Under the Cannabis Act, a cultivation license can sell product to other licensed facilities fostering new business to business relationships and the ability to create quick strategic partnerships as the market becomes established. All starting materials sold as clones to other cultivators have a flower buy back program with Experion. As well, Experion can also sell clones for medical purposes to qualified individuals as a licensed medical supplier.

International Market:

In June 2019, Experion signed a non-binding letter of intent (“LOI”) with a Polish import and distribution company to export medical flower products to Poland. Under the executed LOI, Experion will export medical flower products to Poland for scientific purposes enabling the Polish company to test and develop Experion’s flower products. After the successful completion of this testing, Experion will export its flower products to Poland for consumer medical use. Experion is currently working towards European Union Good Manufacturing Practice (“GMP”) certification of its Mission facility in British Columbia, which will allow the export of cannabis to the EU for medical consumption. Experion is actively seeking export opportunities in Europe and plans to continue to build its international distribution chain.

Corporate Update

During the current period, Experion continued to strengthen is executive team and appointed Kamini Hitkari to the position of Chief Financial Officer. The Company also hired Judy-Ann Pottinger to provide comprehensive investor relations and corporate communications services.

On June 10, 2019, Experion changed its name from Viridium Pacific Group Ltd. to Experion Holdings Ltd. and changed its trading symbol from “VIR” to “EXP” on the TSXV. A focused brand strategy, under one corporate brand, will bring alignment to the market and our shareholders.

Link to comment
Share on other sites

  • 1 month later...

FIRE dropped in price. Cv.Debs too

FIRE ... all-data / Last: C$0.90 - 0.01


FIRE.DB ... Last : $76



Risk ——: UnderV / Company -------- : Coupon : Maturity : Db.Price: Y.T.M.
Mod.  :
AD.DB       : 9.53% / Alaris Royalty------: 5.50% : 30-Jun-24 : $  95.75 : 6.54%:
FIRE.DB  : 23.6% / SupremeCannabis 6.00% :  19-Oct-21 : $  85.00 : 14.4%
JE.DB.D  : 45.2% / Just Energy----------: 6.75% : 31-Mar-23 : $  67.50 : 19.8%


The Supreme Cannabis Company Inc. has released its financial and operating results for the fourth quarter and fiscal year ended June 30, 2019.

"We end fiscal 2019 as one of the few Canadian cannabis businesses building sustainable operations and valuable brands, reporting $3.2-million in adjusted EBITDA [net income (loss) excluding fair value changes on growth of biological assets, realized fair value changes on inventory sold or impaired, amortization of property, plant and equipment, and intangible assets, share-based payments, finance expense, loss on disposal of property, plant and equipment, unrealized gains or losses on investments, and income taxes] (1) for the fourth quarter," said Navdeep Dhaliwal, chief executive officer of Supreme Cannabis. "Our positive adjusted EBITDA and significant revenue growth in the fourth quarter reflects the rapid scale of our 7Acres business and continued strong sales pricing for our brands from the provinces as we transition our premium supply to recreational sales channels.

"With strong confidence in our core business, we began fiscal 2020 with two accretive acquisitions that expanded our addressable markets, provided valuable licensed operating assets and focused expertise," Mr. Dhaliwal added. "As we integrate these businesses and realize further efficiencies from our scaled 7Acres operations, we expect all of our brands to meaningfully contribute to the revenue we have forecasted for fiscal 2020. Amidst the noise of this new marketplace, Supreme Cannabis has taken a strategic and disciplined approach to develop a focused business with clear pillars: best-in-class infrastructure, top consumer brands, advanced intellectual property, and high-impact and capital-light exposure to developing international markets."

                                          ($ thousands) 

                                                    Three months ended                     Year ended                
                                             June 30, 2019     June 30, 2018     June 30, 2019     June 30, 2018

Net revenue                                        $19,005            $3,545           $41,833            $8,855
Operating expenses                                  11,564             5,114            38,713            15,866
Net (loss) after taxes                                (421)              234           (14,497)           (7,347)
Basic and diluted (loss) per common share            (0.00)            (0.00)            (0.05)            (0.03)
Adjusted EBITDA (1)                                  3,195            (1,641)           (4,452)           (6,964)


Supreme Cannabis's core recreational flower brand, 7Acres, accounted for the company's marked increase in revenue, growing 443 per cent year over year from $3.5-million in fourth quarter 2018 to $19-million in fourth quarter 2019 and 90 per cent quarter over quarter from $10-million in third quarter 2019.


Supreme Cannabis believes that the company is well positioned to take significant steps forward in fiscal 2020, including:

  • Expected net revenue of between $150-million and $180-million;
  • Expected positive adjusted EBITDA (1) on aggregate over the course of the year;
  • 7Acres to complete its transition from a wholesale business to premium consumer brand by third quarter fiscal 2020, with complete in-house packaging capabilities for all flower products under the 7Acres brand;
  • Pursuing non-dilutive financing with Tier 1 banks and other lenders to provide financial flexibility for future growth initiatives;
  • Fully financed to execute on all planned initiatives.

> https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aFIRE-2810691&symbol=FIRE&region=C

Link to comment
Share on other sites

Canadian Cannabis stocks under pressure

EXP-etc ... update : +etc : 10d / Last: C$0.15, WEED: $0.00, FIRE: $0.90


4 days ago - 
Weed stocks fell on Thursday after Hexo, a Canadian cannabis company,
+ withdrew its full-year revenue guidance at an investor event Thursday, citing market uncertainty.
Shares of Hexo fell as much as 26% on the news.
The stocks of Tilray (TLRY), Aurora Cannabis (ACB.t), Canopy Growth (CGC), and Cronos (CRON) also slipped.
The weed industry is facing increased uncertainty and the environment will likely continue to be difficult,
according to W. Andrew Carter, an analyst at Stifel.
Link to comment
Share on other sites

  • 1 month later...

Cannabis Extracts Will Propel Industry’s Rise

Longtime readers will remember the first time I put cannabis investing on your radar.

That was over two years ago.

At the time, there were only a couple dozen publicly traded cannabis companies. Today, there are over 300.

New ones seem to be popping up each week. Others are merely adding “cannabis” or cannabis-related words to their company names to tap into the green gold rush.

Link to comment
Share on other sites

Cannabis earnings: How much worse can it get for underperforming weed companies? MarketWatch

After previous disappointments slashed large valuations, a swath of weed earnings is about to hit just ahead of reporting deadline

Getty Images
The cannabis industry has not grown as much as investors expected.

By MaxA. Cherney


Cruelty, thy name is earnings — for weed companies, anyway.

Cannabis companies in Canada have consistently over-promised and under-delivered for investors at earnings time, failing to achieve promised profitability, failing to hit guidance offered only weeks before earnings results, and struggling to sell enough product in Canada or elsewhere to justify their fattened valuations.

That is a big reason that those valuations have been on a severe diet: Since recreational marijuana was legalized in Canada last year, the ETFMG Alternative Harvest ETF MJ, +3.31%  has dropped 43%, Horizons Marijuana Life Sciences Index ETF HMMJ, +5.77%  has been sliced in half, and the Cannabis ETF THCX, +4.66%  , which made its debut in July, has fallen 37%. The benchmark S&P 500 index SPX, -0.38%  has gained 23% during the year.

. . .

While short sellers are continuing to bet against weed companies, not everyone thinks there is more to lose. Cantor Fitzgerald initiated coverage of the sector this week, calling a bottom to the market. Analyst Pablo Zuanic wrote that valuations are at two-year lows, which makes the largest names in the sector attractive.


Here is what to expect from some of the largest cannabis companies.

Cronos Group Inc.

According to a report from Cowen analyst Vivien Azer, Cronos CRON, +2.62% CRON, +2.59%  distributes to the smallest number of provinces — it hasn’t yet entered Quebec, Canada’s second-most-populous province, and just recently expanded into Alberta. “While Cronos has announced multiple third-party supply deals to improve its effective capacity, we have yet to see meaningful progression on improved distribution into the provinces,” Azer wrote.

Cronos continues to have a significant advantage compared with its peers in the form of a $1.8 billion investment from Altria Group Inc. MO, +0.10%  . The company elected to use some of that cash to buy Lord Jones, a U.S. CBD brand; prior to the acquisition, Cronos did not have hemp or CBD-related assets in the U.S., unlike some major rivals.

For more: Cronos paid $300 million for a small CBD company, and CEO’s private-equity firm stands to collect $120 million of it

Analysts polled by FactSet are expecting losses of 3 cents a share on revenue of C$13.7 million ($10.4 million). Cronos is set to announce earnings Tuesday before the opening bell and will have a conference call at 8:30 a.m. Eastern time.

Tilray Inc.

Tilray TLRY, +4.70%  faces analyst expectations for a tough quarter. MKM Partners analyst Bill Kirk wrote in a note to clients that he is expecting high inventory levels at the retail and cultivator segments of the market will pressure shipments and pricing from Tilray.

For more: One year on, Canada’s legal cannabis market is down but not out

Kirk wrote in a note to clients that forward expectations for Tilray still remain too high and are based on the expectation that profitability is likely to improve. Profitability isn’t going to improve, Kirk writes, because cannabis prices would have to hold — they are declining as more supply becomes available — brands would have to expand into new markets, and export markets would need to demand Canada-grown cannabis.

Analysts polled by FactSet expect losses of 30 cents a share on sales of $49 million. Tilray is expected to release earnings after the closing bell Tuesday, and will host a conference call at 5 p.m. Eastern time.

Aurora Cannabis Inc.

Aurora ACB, +2.27% ACB, +12.54%  disappointed investors the last time earnings were reported, and the numbers are expected to get worse this time around.

As a result of the increased amount of weed available, sales of recreational cannabis are expected to decline by roughly 7% compared with the prior quarter, according to Azer. Azer wrote in a note that Aurora has said that its wholesale business — which delivered C$20 million in the fiscal fourth quarter — is unlikely to produce revenue for the fiscal first quarter.

The company originally targeted profitability on an “adjusted earnings before interest taxes depreciation and amortization” basis by the fourth quarter, but failed to come through.

Read: Aurora Cannabis covets California’s weed culture, but can’t pronounce one word correctly

“We forecast ACB’s loss to expand in 1Q20, driven by lower operating leverage from the reduction in revenue from the wholesale segment,” Azer wrote. The analyst added that she expected medical weed sales in Canada and abroad to be flat.

Analysts expect losses of 5 cents a share on sales of C$89.7 million, according to FactSet. Aurora is expected to release results after the market closes Thursday, and a conference call with analysts is set for 6 p.m. Eastern.

Canopy Growth Corp.

The world’s largest cannabis company by market value avoided tumult during the quarter more than it has in the past, and recently announced a product lineup for changing regulations that will allow sales of edibles, drinks and vapes in Canada. Azer notes that Canopy CGC, +3.85% WEED, +15.66%  sales have mostly been flat since recreational legalization, and may remain so for a while.

“We would expect another similar quarter, normalizing for the 1Q20 oil adjustment, although we believe that the company is setting up for more robust growth in the December Q (3Q20), mostly reflecting the impact from newly added new stores,” Azer wrote.

See also: Drake is trying to trademark Canada’s pot warning label, and may be in for a fight

Azer also said that Canopy may pick up more medical patients from CannTrust Holdings Inc. CTST, +6.88% , which has halted all weed sales after revelations surfaced that it had been growing weed in unlicensed rooms.

One new wrinkle to watch for: Canopy executives have said the company will move to reporting under U.S. generally accepted accounting principals, or GAAP, like Tilray. Currently, like most Canadian companies, Canopy reports the international financial reporting standards, or IFRS.

Wall Street expects second-quarter losses of 41 cents a share on sales of C$101.5 million, according to FactSet. Canopy is set to release financial results before the market opens Thursday, and will host a conference call at 8:30 a.m. Eastern. Acreage Holdings Inc. ACRGF, +23.08%  , which Canopy has purchased the right to buy in the future upon changes to marijuana’s legal status in the U.S., is set to report Tuesday after the market closes. Its conference call is scheduled for 8:30 a.m. Eastern on Wednesday.

Canopy Rivers Inc. RIV, +0.81% , which was spun out of Canopy Growth because of changes in how Canadian exchanges viewed companies holding U.S. cannabis assets, is scheduled to report its results before the market opens Thursday, with a conference call at 10 a.m. Eastern.

The rest

• Sundial Growers Inc. SNDL, -3.47%  reports earnings Wednesday after the closing bell. The call is at 5 p.m. Eastern. MarketWatch has previously reported the company had to return a half-ton of bad weed.

• Aleafia Health Inc. ALEAF, +8.62% ALEF, +5.88%  reports third-quarter results Tuesday before the opening bell and its call is scheduled for 8:30 a.m. Eastern time.

• Terra Tech Corp. TRTC, +10.59%  is expected to report earnings after the closing bell Tuesday and has scheduled a call for 4:30 p.m. Eastern.

• Charlotte’s Web Holdings Inc. CWEB, +10.59% CWBHF, +10.61%  is scheduled to release earnings before the opening bell Wednesday and has a call at 8 a.m. Eastern.

• Green Organic Dutchman Holdings Inc. TGOD, +21.92% TGODF, +22.15%  is expected to report results after the closing bell Thursday and has a conference call scheduled for Friday at 9 a.m. Eastern.

• The Supreme Cannabis Co. Inc. FIRE, +7.69% SPRWF, +4.43%  is expected to report earnings Thursday.

/ 2 /

2 Stocks That Soared Higher on Tuesday

Motley Fool-20 hours ago
Today, certain markets and indexes closed lower, but here is a pair of stocks that ignored the overall trend and headed skyward. Without further ...

Canopy Growth

Marijuana stocks, which have been among the market's worst performers of late, received a much-needed piece of hopeful news on Tuesday.

It came from the House of Representatives, specifically that body's Judiciary Committee. The committee said that on Wednesday morning it will mark up -- i.e., discuss, debate, and likely modify -- the Marijuana Opportunity Reinvestment and Expungement (MORE) Act.

This sprawling proposed law would "deschedule" (i.e., remove) marijuana from the federal government's list of controlled substances. It would also enact a set of other cannabis-related legal changes, such as a federal tax on marijuana products.

Marijuana stock investors were cheered by the news, which clearly shows that the political will exists for badly needed cannabis legal reform. Shares of certain cannabis companies, battered by the sector's weak profitability and factors like supply challenges in Canada and heavy taxation in the U.S., rose in sympathy.

One of the major risers (to the tune of nearly 8% on the day) was Canopy Growth (NYSE:CGC), a bellwether in this industry. It's possible that investors consider Canopy Growth's cash, cash equivalents, and marketable securities position of over $2.7 billion to be a thick enough cushion to help it get through these difficult times for the industry.

There's also the bottom-feeder aspect of marijuana stocks. Given how far they've fallen so far this year -- Canopy Growth is still down by 43%, even with the Tuesday pop factored in -- some investors consider them to be bargains at the moment.

While the MORE Act news is certainly welcome, like other marijuana reform legislation it's a long way from House committee markup to law of the land. The Senate still has a Republican majority, and many of those lawmakers are not in favor of adjusting current drug legislation.

Link to comment
Share on other sites

  • 1 month later...

African Pot growers are thriving...

FP/wire say Supreme Cannabis sees Lesotho growing

2019-12-23 09:42 ET - In the News

Also In the News (C-APHA) Aphria Inc
Also In the News (C-WEED) Canopy Growth Corp

The Financial Post reports in its Monday edition that Kekeletso Lekaota spends her work days nurturing rows of cannabis plants for harvest. A Bloomberg dispatch to the Post says that it is a crop that Ms. Lekaota had no experience with 18 months ago, when she saw an advertisement for a grower in her local newspaper. Now, the 27-year-old trains others how to cultivate the plants for MG Health, a supplier of pharmaceutical-grade cannabis products, at a farm and oil-extraction facility in Lesotho, the tiny, mountainous kingdom bordered on all sides by South Africa. Foreign investors including Canadian companies Supreme Cannabis, Canopy Growth and Aphria have since poured tens of millions of dollars into a handful of facilities, drawn by the low cost of production. MG Health, Lesotho's biggest commercial producer, received $10-million from Supreme Cannabis last year in exchange for 10 per cent of the business then known as Medigrow Lesotho Supreme has said that it eventually wants to export medical cannabis oils from Lesotho to Canada. MG Health plans to employ as many as 3,000 workers locally -- up from about 350 currently -- once it reaches full production in a few years. The company's primary market is South Africa.

Link to comment
Share on other sites

  • 2 weeks later...

Canaccord vs- a "Cannabis cluster" of stocks

CF vs-MJ, WEED.t, FIRE.t ... update : Last: C$4.84/ MJ: $16.73 = r-28.9%


Ratio: C$4.84/ MJ: $16.73 = r-28.9%



Link to comment
Share on other sites

News for Supreme Cannabis Co. Inc.

  1. Monday, January 06, 2020

    1. Cannabis stocks led lower by Aurora and Hexo MarketWatch

    2. Hexo Corp. and Aurora Cannabis Inc., shares were leading weed stocks mostly lower Monday, adding to what is likely to shape up to be a third straight day of losses in 2020.

      In afternoon trading, shares of Aurora Cannabis ACB, -3.68% ACB, -2.85%  were down 5% after the company listed an Exeter, Ontario greenhouse for C$17 million, which at one point was expected to produce over 105,000 kilograms of marijuana a year. Aurora ended up with the compound after it acquired MedReleaf, which originally bought the property for C$21.5 million in cash and over 200,000 shares of MedReleaf stock.

      In a note to investors Monday, MKM Partners analyst Bill Kirk wrote that Aurora’s failure to license the facility and sell cannabis grown there suggests that Aurora will likely write down a “large amount” of goodwill — roughly C$2 billion — in the future. As MarketWatch has previously reported, Aurora accumulated more than C$2.11 billion in goodwill from its MedReleaf acquisition

    1. Supreme Cannabis CEO Navdeep Dhaliwal has left the company MarketWatch

    2. Supreme Cannabis names Colin Moore as interim CEO MarketWatch

  2. OLDER: Tuesday, November 12, 2019

    1. Cannabis earnings: How much worse can it get for underperforming weed companies? 

    2. Tuesday, August 13, 2019

      1. Supreme Cannabis sees fiscal 2020 revenue C$150 mln-C$180 mln; FactSet consensus C$129.7 mln MarketWatch

      2. Supreme Cannabis sees Q4 revenue C$19 mln vs. C$3.55 mln a year ago; FactSet consensus C$12.7 mln MarketWatch

Link to comment
Share on other sites

  • 10 months later...

FIRE / Supreme Cannabis ... 2yr: YTD: Last: 0.145 / FIRE.DB - T  

0.1 49.50 · 62.50 0.1 50.00  


Supreme Cannabis earns $29.76-million in Q1

2020-11-16 17:21 ET - News Release

Ms. Beena Goldenberg reports


The Supreme Cannabis Company Inc. has released its financial and operating results for the three months ended Sept. 30, 2020.

2021 first quarter highlights:

  • Positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $300,000;
  • 24-per-cent net revenue growth quarter over quarter;
  • 45 active retail SKUs (stock-keeping units), with presence in all 10 provinces;
  • Completed the third shipment of medical cannabis to Israel through its Truverra brand;
  • Maintains a strong liquidity position, including a cash balance of $20.4-million.

Subsequent to quarter-end:

  • Entered into a supply agreement with Medical Cannabis by Shoppers Inc., a subsidiary of Shoppers Drug Mart Inc., to offer Truverra-branded medical cannabis products through the Medical Cannabis by Shoppers on-line sales platform accessible to patients across Canada.

Supreme Cannabis's management discussion and analysis (MD&A) and condensed interim consolidated financial statements for the three months ended Sept. 30, 2020 (Q1 2021), along with all previous public filings of the company, may be found on SEDAR. All figures are in Canadian dollars.

...  Balance sheet, liquidity and cash flow from operations

Supreme Cannabis ended the quarter with a total cash balance of $20.4-million and a working capital surplus of $48.1-million.

During the first quarter of fiscal 2021, the company significantly strengthened its balance sheet by refinancing its convertible debentures and amending its three-year term credit facility consisting of a term loan and a revolving credit facility. As a result, there are no debt maturities for two years (excluding customary principal amortization payments) and the carrying value of total debt was reduced by approximately $71.0-million on the day of the transaction related to the convertible debt extinguishment. Furthermore, expected cash interest expense was significantly reduced due to the reduction in the principal amount of the convertible debentures and the credit facility. The amended credit facility defers the financial covenants related to leverage and the fixed charge coverage ratio by 12 months until Q3 2022.

Operating and capital expenditures

In Q1 2021, the cost realignment efforts resulted in the company achieving a $9.3-million or 59-per-cent decrease in operating expenses, compared with the three months ended June 30, 2020


The company remains confident in its ability to grow near-term revenue and reach sustainable profitability based on its accelerated transformation into a premium cannabis CPG company, its streamlined and rightsized operating structure, and its enhanced offering of new high-quality brands:

  • The company has a robust and growing product line that addresses consumers' needs at a variety of price points and form factors.
  • The company has efficient and effective coast-to-coast sales coverage with the Humble & Fume sales partnership.
  • The company has substantially completed the rightsizing of its operating structure with the right teams in place to deliver against objectives efficiently.
  • Supreme Cannabis remains focused on cost containment and is fully financed to execute on all planned initiatives.

First quarter 2021 earnings conference call and webcast

> MORE: https://www.stockwatch.com/News/Item?bid=Z-C:FIRE-2990674&symbol=FIRE&region=C

Link to comment
Share on other sites

  • 2 months later...

Reddit GAMERS & Robinhoods moved the Cannabis market

C:*MKTPOT - Cannabis Summary for Feb. 11, 2021
[2021-02-11 20:33]
Tilray and others plunge as the Reddit rally runs out of steam (or cash).

Spyder Cannabis makes a curious dart upward. Columbia Care is raising $25-million mere weeks after raising $149-million, and Canopy Rivers talks up its quarterly financials.  more...

The S&P/TSX Cannabis Index plunged 107.82 to 291.12, while the CSE Composite Index lost 55.41 to 975.53. Cannabis stocks crashed as the Reddit rally fizzled. Notable losers included Tilray Inc. (U.TLRY), down $31.75 (U.S.) to $32.16 (U.S.) on 211 million shares, along with its merger target, Aphria Inc. (APHA), down $12.01 to $21.36 on 30.1 million shares. As well, Medmen Enterprises Inc. (MMEN) lost $1.05 to 60 cents on 66.9 million shares, Organigram Holdings Inc. (OGI) lost $3.06 to $4.56 on 31.8 million shares and The Supreme Cannabis Company Inc. (FIRE) lost 9.5 cents to 40.5 cents on 146 million shares. Each of those three tripped the single-stock circuit breaker on the way down. Organigram managed to trip it twice.

There were still a few favourites among day traders. Little Spyder Cannabis Inc. (SPDR), for example, reached an intraday high of 39 cents before closing at 17.5 cents, up 7.5 cents, on 29.6 million shares. Two days ago it was worth 3.5 cents. Its only news in recent weeks had to do with a $200,000 loan that Spyder arranged in January and is using to repay a separate debt of $189,217. When Spyder is not borrowing from Peter to pay Paul, it sells cannabis, electronic cigarettes and vaping accessories out of five stores in Ontario and Calgary. It has negative operating cash flow and "going concern" red flags dotted about its quarterly financials.

> https://www.stockwatch.com/News/Item?bid=Z-C:*MKTPOT-3031095&symbol=*MKTPOT&region=C

I had some FIRE (Supreme Cannabis) shares that I let go ... 3yr: 1yr: 10d / Last: $0.34, down almost 50% from high of 0.60


Link to comment
Share on other sites

UPDATE on the Canna-Cluster

MJ / Alternative Health index, WEED, FIRE, EXP ... update: at ...

12/23/19: $17.14, C$26.27, C$0.66, C$0.105


Canaccord vs- a "Cannabis cluster" of stocks

CF vs-MJ, WEED.t, FIRE.t ... update : Last: C$4.84/ MJ: $16.73 = r-28.9%



Link to comment
Share on other sites

C:*MKTPOT - Cannabis Summary for Feb. 17, 2021
[2021-02-17 20:18]
Supreme Cannabis is tapping the market for cash, again. Medmen Enterprises slips on disappointing financials and a new financing. Cresco Labs expands in Ohio.  more...

Link to comment
Share on other sites

  • 1 month later...

==cl. 0.38 / db=

134.00 · 145.00

Supreme Cannabis shareholders will receive 0.01165872 of a Canopy common share and 0.01 cent in cash

34.73 (- 1.56)  x 0.01166 = 0.405


2021-04-08 08:12 C:FIRE 0.265 News Release Canopy Growth to acquire Supreme Cannabis for $435M


Canopy Growth Corp. and The Supreme Cannabis Company Inc. have entered into a definitive arrangement agreement under which Canopy will acquire all of Supreme Cannabis's issued and outstanding common shares in a transaction valued at approximately $435-million on a fully diluted basis.

Under the terms of the arrangement agreement, Supreme Cannabis shareholders will receive 0.01165872 of a Canopy common share and 0.01 cent in cash in exchange for each Supreme Cannabis share held. The transaction provides Supreme Cannabis shareholders with a premium per Supreme Cannabis share of approximately 66 per cent based on the closing prices of the Supreme Cannabis shares and Canopy common shares on the Toronto Stock Exchange as of April 7, 2021.

The transaction is expected to provide several benefits to both Canopy and Supreme Cannabis shareholders. Notably, following completion of the acquisition, Canopy will possess a strengthened brand portfolio including one of Canada's leading premium brands, 7Acres...

Key transaction highlights:

  • Solidifies Canopy's leadership position in the Canadian recreational market, well positioned for growth: The transaction combines Canopy's pre-eminent position with Supreme Cannabis's top 10 position in Canada to create a pro forma Canadian recreational market share of 13.6 per cent, including 7Acres holding Canada's No. 1 premium flower brand position, No. 1 in PAX vapes and top five in prerolled joints:
    • Combined pro forma market share estimated to be 23.3 per cent of the premium flower segment in Ontario and 21.4 per cent in British Columbia.
  • Adds premium brands to Canopy's portfolio: The addition of Supreme Cannabis's premium brands...

=>  more:

/ 2 /

2021-04-09 09:21 C:WEED 35.75 In the News Globe says Canopy buying Supreme for its primo weed
2021-04-09 08:37 C:WEED 35.75 In the News FP says Canopy Growth, rivals are doing deals


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...